77,922 Biogen Inc. $BIIB Shares Bought by BNP Paribas

BNP Paribas increased its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 1,787.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 82,282 shares of the biotechnology company’s stock after acquiring an additional 77,922 shares during the quarter. BNP Paribas owned about 0.06% of Biogen worth $18,586,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Bell Investment Advisors Inc bought a new position in Biogen in the second quarter valued at about $27,000. Align Financial LLC grew its stake in shares of Biogen by 339.3% during the third quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock worth $28,000 after buying an additional 95 shares during the last quarter. Provenance Wealth Advisors LLC acquired a new position in shares of Biogen during the third quarter worth $29,000. Canton Hathaway LLC acquired a new position in shares of Biogen during the third quarter worth $31,000. Finally, Financial Freedom LLC bought a new position in shares of Biogen in the 3rd quarter valued at $34,000. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

Biogen stock opened at $249.59 on Friday. The firm’s 50 day simple moving average is $236.83 and its 200 day simple moving average is $206.86. Biogen Inc. has a 1-year low of $160.36 and a 1-year high of $261.00. The firm has a market capitalization of $36.89 billion, a PE ratio of 106.66, a price-to-earnings-growth ratio of 2.83 and a beta of 0.10. The company has a current ratio of 1.95, a quick ratio of 1.37 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.63 billion. Biogen had a return on equity of 9.38% and a net margin of 3.37%. Biogen’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the firm posted $4.81 EPS. As a group, analysts expect that Biogen Inc. will post 12.46 earnings per share for the current fiscal year.

Biogen News Roundup

These are some of the BIIB news items that stood out recently:

  • Positive Sentiment: Biogen and Eisai reported that lecanemab slowed clinical decline over 18 months in an analysis of early Alzheimer’s patients with α-synuclein co-pathology. The subgroup results were exploratory and post hoc, but add supportive evidence for LEQEMBI’s potential reach. Article
  • Positive Sentiment: Coverage also highlighted three-year real-world LEQEMBI data reporting slower Alzheimer’s progression, another potential support for the drug’s commercial prospects. Article
  • Negative Sentiment: A report of elevated buying in BIIB put options points to some investor hedging or bearish positioning, though the headline provides no details on the size or significance of the activity. Article

Analysts Set New Price Targets

Several equities research analysts recently commented on BIIB shares. Citigroup reiterated a “neutral” rating on shares of Biogen in a research report on Wednesday, October 28th. Bank of America lifted their price target on shares of Biogen from $219.00 to $244.00 and gave the company a “neutral” rating in a research note on Thursday, October 22nd. Needham & Company LLC reissued a “buy” rating on shares of Biogen in a research note on Wednesday. Wall Street Zen downgraded Biogen from a “strong-buy” rating to a “buy” rating in a report on Sunday. Finally, UBS Group raised their price objective on shares of Biogen from $270.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $255.45.

Read Our Latest Research Report on Biogen

Biogen Company Profile

(Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

Recommended Stories

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.